Preoperative stereotactic body radiotherapy combined with surgical treatment for renal cell carcinoma and inferior vena cava tumour thrombus: study protocol for a single-arm cohort trial

Author:

Liu YunchongORCID,Liu Zhuo,Peng Ran,Xiao Ruotao,Wang Junjie,Wang Hao,Ma Lulin

Abstract

IntroductionAlthough surgery is currently the first choice for patients with renal cell carcinoma and vena cava tumour thrombus, the surgery is difficult, with many complications, and the prognosis of patients is not ideal. Renal cell carcinoma is not sensitive to traditional radiotherapy, but the development of stereotactic ablative body radiotherapy (SABR) technology with the characteristics of high precision, dose and conformity has made the radiotherapy of renal cell carcinoma reexamined.Methods and analysisStudy designThis trial is a single-arm cohort study sponsored by Peking University Third Hospital.Study treatmentPreoperative stereotactic ablative radiotherapy combined with surgical treatment.Primary endpoints(1) Adverse reactions after 4–6 weeks of SABR. (2) Mayo staging of tumour thrombus. (3) The length of the tumour thrombus from the corresponding anatomical mark. (4) Invasion of the inferior vena cava wall. (5) Recurrent-free survival rate of the tumour. (6) Cancer-specific survival rate. (7) Overall survival rate. (8) Perioperative indicators including operation time, intraoperative bleeding volume and postoperative complications.Secondary endpoints(1) The longest diameter of the tumour and (2) Lymph node condition.Main inclusion criteriaPatients with renal cell carcinoma and inferior vena cava tumour thrombus graded from Mayo II to IV and eligible for radical nephrectomy and inferior vena cava thrombectomy.Main exclusion criteriaPatients with previous targeted therapy, chemotherapy or other interventions, or who cannot tolerate SABR or surgery.Planned sample size20 patients.Ethics and disseminationThe trial protocol and the informed consent of the subjects were submitted and approved by the Peking University Biomedical Ethics Committee.Trial registration numberChiCTR1800015118.

Funder

Peking University

Publisher

BMJ

Subject

General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3